NeuroReport 24:161-166 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. NeuroReport 2013, 24: 161-166″
“The present study investigated a possible antidepressant-like activity
of bis selenide using two predictive tests for antidepressant effect on rodents: the forced swimming test (FST) and the tail suspension test (TST). Bis selenide (0.5-5 mg/kg, p.o.) decreased the immobility time in the mouse FST and TST. The anti-immobility effect of bis selenide (1 mg/kg, p.o.) in the TST was prevented by the pretreatment of mice with p-chlorophenylalanine Blebbistatin datasheet methyl ester (PCPA; 100 mg/kg, i.p., an inhibitor of serotonin synthesis), ketanserin ( 1 mg/kg, i.p., a 5-HT2A/2C receptor antagonist), and ondasentron (11 mg/kg, i.p., a 5-HT3 receptor antagonist). Pretreatment of mice with prazosin (1 mg/kg, i.p., an alpha(1)-adrenoceptor antagonist), yohimbine (I
mg/kg, i.p.. an alpha(2)-adrenoceptor antagonist), propranolol (2 mg/kg, i.p., beta-adrenoceptor antagonist), SCH23390 PF299804 supplier (0.05 mg/kg, s.c., a dopamine D-1 receptor antagonist), sulpiride (50 mg/kg, i.p., a dopamine D-2 receptor antagonist), or WAY 100635 (0.1 mg/kg, s.c., a selective 5-HT1A receptor antagonist) did not block the antidepressant-like effect of bis selenide ( I mg/kg, p.o.) in the TST. Administration of his selenide (0.1 mg/kg, p.o.) and fluoxetine (1 mg/kg), at subeffective doses, produced an antidepressant-like effect in the TST. Bis selenide did not alter Na+ K+ ATPase, MAO-A and MAO-B activities in whole brains of mice. Bis selenide produced an antidepressant-like effect in the mouse TST and FST, which may be related to the serotonergic system (5-HT2A/2C and 5-HT3 receptors). (C) 2009 Elsevier Inc. All rights reserved.”
of bone mineral metabolism and vascular calcification are prevalent in patients with kidney failure. Clinical management is based on biochemical targets, in particular parathyroid hormone (PTH) concentrations, but this has many limitations including high biological variation. A possible alternative is bone-specific alkaline phosphatase (ALP); therefore, we evaluated the biological variation of this marker in patients undergoing hemodialysis. Bone ALP was I-BET151 research buy measured in non-fasting serum samples taken twice a week over a 6-week period in 22 stable hemodialysis patients and 12 healthy volunteers. The within-individual coefficients of variance were calculated and used to derive the critical difference required to be certain that an observed change was significant. The coefficient of variance for bone ALP was significantly higher in hemodialysis patients compared to healthy individuals. Seven samples were required to estimate the homeostatic set point of bone ALP, within 10%, in a hemodialysis patient. The concentration of serial bone ALP measurements would need to change by 36% between any two measurements before it can be considered a significant change.